OnconetixONCO +0.44%23 Gross Margin % is -9.52% as of Mar. 2026. GuruFocus rates ONCO with a GF Score™ of 23/100. The stock has 4 warning signs investors should review. Among 734 Biotechnology companies, Onconetix ranks better than 72.07% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Onconetix's Gross Profit for the
three
months ended in Mar. 2026 was $-0.00 Mil. Onconetix's Revenue for the
three
months ended in Mar. 2026 was $0.02 Mil. Therefore, Onconetix's Gross Margin % for the quarter that ended in Mar. 2026 was -9.52%.
The historical rank and industry rank for Onconetix's Gross Margin % or its related term are showing as below:
ONCO'
s Gross Margin % Range Over the Past 10 Years
Min: -1943.1 Med: 41.8 Max: 79.73
Current: 79.73
During the past 7 years, the highestGross Margin % of Onconetix was 79.73%. The lowest was -1943.10%. And the median was 41.80%.
ONCO's Gross Margin % is ranked better than 72.07% of 734
companies
in the Biotechnology industry
Industry Median: 60.795
vs ONCO: 79.73
Onconetix had a gross margin of -9.52% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Onconetix was 0.00% per year.
Onconetix (NAS:ONCO) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Onconetix had a gross margin of -9.52% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Onconetix Gross Margin % Related Terms
Onconetix Gross Margin % Historical Data
* Premium members only.
The historical data trend for Onconetix's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ONCO vs CMND, REVB, PPCB: Gross Margin % Comparison
For the Biotechnology subindustry, Onconetix's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Onconetix Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Onconetix's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Onconetix's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Onconetix (ONCO) has a Gross Margin % of -9.52% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Onconetix and its competitors. According to the industry distribution chart, Onconetix ranks #205 out of 734 companies in the Biotechnology industry, placing it in the top 27.9%.
Is Onconetix's Gross Margin % too high?
Onconetix's current Gross Margin % is -9.52%. Based on the distribution chart, Onconetix ranks #205 out of 734 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Onconetix has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Onconetix's Gross Margin % compare to CMND and REVB?
According to the Biotechnology industry distribution chart, Onconetix ranks #205 out of 734 companies for Gross Margin %. This puts Onconetix in the upper half of its industry. The industry median Gross Margin % is 60.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.80, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Onconetix and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Onconetix's current Gross Margin % is -9.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Onconetix stock overvalued right now?
Onconetix (ONCO) has a current Gross Margin % of -9.52%. The current Gross Margin % is -9.52%. Onconetix's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Onconetix (ONCO), the current Gross Margin % is -9.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
23GF Score
Get the complete analysis for ONCO
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ONCO has been successfully added to your 
